Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations

Mario Cruciani, Marina Malena Center of Community Medicine and HIV Outpatient Clinic, Infectious Diseases Unit, San Bonifacio Hospital, Verona, Italy Abstract: The current standard of care for human immunodeficiency virus (HIV) treatment is a three-drug regimen containing a nonnucleoside reverse...

Full description

Bibliographic Details
Main Authors:	Cruciani M, Malena M
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-02-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/combination-dolutegravirndashabacavirndashlamivudine-in-the-management-peer-reviewed-article-PPA

Similar Items

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
by: Santiago Moreno Guillen, et al.
Published: (2017-09-01)

Abacavir/lamivudine combination in the treatment of HIV: a review
by: Geetha Sivasubramanian, et al.
Published: (2010-02-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
by: Bagella P, et al.
Published: (2019-05-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
by: Kandel CE, et al.
Published: (2015-07-01)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
by: Putcharoen O, et al.
Published: (2015-10-01)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
by: Andrea Giacomelli, et al.
Published: (2020-06-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
by: Jones JD, et al.
Published: (2013-08-01)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
by: Taha H, et al.
Published: (2015-10-01)

Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice
by: Sandra Medina-Moreno, et al.
Published: (2020-03-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
by: Alberto Borghetti, et al.
Published: (2019-01-01)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)

Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia
by: Elisabeth Petit, et al.
Published: (2018-01-01)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
by: Torsak Bunupuradah, et al.
Published: (2015-07-01)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
by: Julián Olalla, et al.
Published: (2018-10-01)

Simultaneous Determination of Lamivudine, Zidovudine and Abacavir in Tablet Dosage Forms by RP HPLC Method
by: D. Anantha Kumar, et al.
Published: (2010-01-01)

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
by: Rosa De Miguel, et al.
Published: (2020-05-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
by: Squires KE, et al.
Published: (2017-03-01)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
by: Nadia Galizzi, et al.
Published: (2018-01-01)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
by: Jesús Troya, et al.
Published: (2018-01-01)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016-02-01)

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Sharlene Ho, et al.
Published: (2020-05-01)

Clinical utility of azilsartan&ndash;chlorthalidone fixed combination in the management of hypertension
by: Shuster JE, et al.
Published: (2012-06-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
by: Jesús Troya, et al.
Published: (2016-01-01)

Valsartan combination therapy in the management of hypertension &ndash; patient perspectives and clinical utility
by: David T Nash, et al.
Published: (2009-10-01)

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
by: Ahrens I, et al.
Published: (2014-02-01)

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons
by: Natascha D. Diaco, et al.
Published: (2018-12-01)

Clinical utility of fixed-combination telmisartan&ndash;amlodipine in the treatment of hypertension
by: Segura J, et al.
Published: (2011-05-01)

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
by: Jesús Troya, et al.
Published: (2017-01-01)

Bioequivalence study of abacavir/lamivudine (600/300-mg) tablets in healthy Thai volunteers under fasting conditions
by: Ekawan Yoosakul, et al.
Published: (2016-02-01)

Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era
by: Valeria Cento, et al.
Published: (2021-04-01)

The role of dolutegravir in the management of HIV infections
by: Miller MM, et al.
Published: (2015-02-01)